We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
-$256M
Cap. Flow %
-30.4%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 15.86%
2 Consumer Staples 0.43%
3 Consumer Discretionary 0.12%
4 Materials 0.09%
5 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGLT
226
DELISTED
Egalet Corporation
EGLT
– –
-73,792
Closed -$74K
ANTH
227
PUT
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-658
Closed -$109K
ONSIZ
228
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
– –
-199,193
Closed -$4K
JUNO
229
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-3,003
Closed -$13.7M
CYTXW
230
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
– –
-1,028,634
Closed -$29.1K
SPHS
231
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-55,907
Closed -$121K
6 7 8 9
10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.